Scimago Lab
powered by Scopus
call: +1.631.470.9640
Mon-Fri 10 am - 2 pm EST


Medical Science Monitor Basic Research


eISSN: 1643-3750

Get your full text copy in PDF

Comparative assessment of 200/0.5 HAES 6% and Gelafundin in the treatment of hypovolaemia in post-coronary bypass patients

Beata Dytkowska, Zbigniew Karwacki, Janina Suchorzewska, Maria Wujtewicz

Med Sci Monit 1998; 4(6): CR1000-1003

ID: 451758

40 patients after operations of coronary bypass in extracorporeal circulation were examined in order to evaluate usefulness of 200/0.5 HAES 6% and Gelafundin. The patients were divided into 2 groups, depending on received drug (group I - HAES, group 2 - Gelafundin). A single dose of up to 15 ml/kg b. m. of colloids was given to patients with diagnosed symptoms of hypovolaemia, haematocrit values over 30%. The following parameters were investigated: systolic, diastolic, mean arterial blood pressure, measured directly, as well as central venous pressure (CVP). The measurements were taken before the onset of infusion, as well as in 15, 30, 45, 60 minute of infusion and 15, 30 minutes after its completion. Biochemical parameters such as haemoglobin, haematocrit, number of platelets, albumin concentration, osmolality and selected blood clotting parameters were investigated before as well as 30 minutes after administration of the drugs. At the end of drug infusion, both groups demonstrated statistically significant increase of systolic and mean arterial blood pressure as well as central venous pressure. No significant effect of administered colloids upon biochemical parameters was
observed. Both HAES and Gelafundin were well tolerated by the patients. No allergic reactions were observed either during infusion or after its completion.
key words:    coronary bypass • postoperative treatment • hypovolaemia

This paper has been published under Creative Common Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) allowing to download articles and share them with others as long as they credit the authors and the publisher, but without permission to change them in any way or use them commercially.
I agree